Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01321879 · ClinicalTrials.gov registry record · Phase 2
Study to Evaluate the Safety and Efficacy of Telavancin in the Treatment of Gram Positive Bloodstream Infections in Cancer Patients
A Phase 2 study of Infection and Bacteremia, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
- 1
- Study location
NCT01321879 is a Phase 2 study of Infection and Bacteremia that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 40 participants, below the 725-participant average among 41 other Infection trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01321879, a Phase 2 study of Infection and Bacteremia, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this clinical research study is to learn if Vibativ (telavancin) can help to control blood stream infections (BSIs). The safety of this treatment will also be studied. Objectives: Evaluate the clinical efficacy and safety of Telavancin given for treatment of gram positive bacteremia in cancer patients (including neutropenics).
Conditions Studied
Interventions
- DRUG Telavancin
Study Locations (1)
Texas
- University of Texas MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2011-03 |
| Est. Completion | 2016-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01321879
The ClinicalTrials.gov registry entry for NCT01321879 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 725-participant average among 41 other Infection trials with a reported enrollment target (94% lower). The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Infection appearing as the primary indexed condition, and to 1 intervention - of which Telavancin is the first listed.
NCT01321879 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT01321879 about?
NCT01321879 is a clinical study titled "Study to Evaluate the Safety and Efficacy of Telavancin in the Treatment of Gram Positive Bloodstream Infections in Cancer Patients". The goal of this clinical research study is to learn if Vibativ (telavancin) can help to control blood stream infections (BSIs). The safety of this treatment will also be studied. Objectives: Evaluate the clinical efficacy and safety of Telavancin given for treatment of gram positive bacteremia in...
What is the current status of trial NCT01321879?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2011-03. Estimated completion is 2016-12.
What conditions does trial NCT01321879 study?
This clinical trial studies the following conditions: Infection, Bacteremia.
What interventions are being tested in trial NCT01321879?
The interventions under investigation include: Telavancin (DRUG).
Who is sponsoring clinical trial NCT01321879?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01321879 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Infection
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant For Hematological Cancer
COMPLETED · Phase 2
-
Topical PluroGel PN for the Treatment of Mildly Infected Diabetic Foot Ulcers
COMPLETED · Phase 2
-
Home Hospital for Suddenly Ill Adults
RECRUITING · NA
-
Copper Supplementation in Cirrhosis
RECRUITING · NA
-
Persona Revision Knee System Outcomes
RECRUITING
-
NADPH Oxidase Correction in mRNA-transfected Granulocyte-enriched Cells in Chronic Granulomatous Disease (CGD)
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.